Item Posts Archive - Page 23 of 1770 - Medivizor
Navigation Menu

Evaluating the effectiveness and safety of busulfan plus cyclophosphamide versus total body irradiation plus cyclophosphamide for patients with adult B-cell acute lymphoblastic leukemia.

Evaluating the effectiveness and safety of busulfan plus cyclophosphamide versus total body irradiation plus cyclophosphamide for patients with adult B-cell acute lymphoblastic leukemia.

Posted by on Mar 26, 2023 in Leukemia | 0 comments

In a nutshell This study evaluated the effectiveness and safety of busulfan (Bu; Busulfex) plus cyclophosphamide (Cy; Cytoxan) (BuCy) regimen versus total body irradiation (TBI) plus cyclophosphamide (TBI-Cy) regimen for patients with adult B-cell acute lymphoblastic leukemia (B-ALL) in first complete remission undergoing allogeneic hematopoietic...

Read More

Comparing darolutamide, apalutamide and enzalutamide for treating non-metastatic castration-resistant prostate cancer.

Comparing darolutamide, apalutamide and enzalutamide for treating non-metastatic castration-resistant prostate cancer.

Posted by on Mar 26, 2023 in Prostate cancer | 0 comments

In a nutshell The study compared the effectiveness of darolutamide (Nubeqa), apalutamide (Erleada), and enzalutamide (Xtandi) in treating non-metastatic castration-resistant prostate cancer (nmCRPC). The data showed that darolutamide, apalutamide, and enzalutamide were similarly effective and improved survival outcomes compared to placebo...

Read More

Evaluating the effectiveness and safety of the Pfizer/BioNTech BNT162b2 COVID-19 vaccine in patients with breast and gynecological cancer.

Evaluating the effectiveness and safety of the Pfizer/BioNTech BNT162b2 COVID-19 vaccine in patients with breast and gynecological cancer.

Posted by on Mar 24, 2023 in Breast cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of the Pfizer/BioNTech BNT162b2 COVID-19 vaccine in patients with breast and gynecological cancer. The data showed that most patients with breast and gynecological cancer developed antibodies after the second dose of the vaccine. However, the authors suggested that for non-responders or weak...

Read More

Evaluating the effectiveness and safety of oral paclitaxel plus encequidar versus intravenous paclitaxel in patients with metastatic breast cancer.

Evaluating the effectiveness and safety of oral paclitaxel plus encequidar versus intravenous paclitaxel in patients with metastatic breast cancer.

Posted by on Mar 24, 2023 in Breast cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of oral paclitaxel (Taxol) plus encequidar (HM 30181) versus intravenous (IV) paclitaxel in patients with metastatic breast cancer (BC). This study concluded that oral paclitaxel plus encequidar was more effective than IV paclitaxel with manageable side effects in these...

Read More

Evaluating the safety and effectiveness of different doses of asundexian in patients with acute myocardial infarction treated with dual antiplatelet therapy.

Evaluating the safety and effectiveness of different doses of asundexian in patients with acute myocardial infarction treated with dual antiplatelet therapy.

Posted by on Mar 16, 2023 in Coronary artery disease | 0 comments

In a nutshell This study investigated the safety and effectiveness of different doses of asundexian (BAY 2433334) in patients with acute myocardial infarction (MI; heart attack) treated with dual antiplatelet therapy (DAPT). The data showed that asundexian 50 mg when added to DAPT inhibits blood clotting factor XIa by more than 90% without...

Read More
ABOUT USHOW IT WORKSBLOG NEWS PARTNERS CONTACT US PRIVACY POLICY TERMS OF USE
FROM OUR BLOG
LATEST NEWS
CONNECT WITH US
© 2024 Medivizor